Literature DB >> 17928499

Evolution of lung nodules < or =5 mm detected with low-dose CT in asymptomatic smokers.

M Bellomi1, G Veronesi, C Rampinelli, S Ferretti, E De Fiori, P Maisonneuve.   

Abstract

Low-dose CT is widely employed for the early diagnosis of lung cancer in high-risk populations even if screening programmes have not been clinically validated yet; however, the optimum follow-up schedule for small lung nodules of uncertain status has not been defined. The aim of this study was to assess outcomes for small pulmonary nodules (diameter < or =5 mm) detected by CT in asymptomatic smokers In 2000-2001, 1035 high-risk people were enrolled in an observational study for the early detection of lung cancer by yearly CT. The prevalence, incidence and evolution of small lung solid nodules are described 238 solid lung nodules < or = 5 mm were identified at initial low-dose CT in 165 people (prevalence 15.9%). 26% of them were not detected in the following 4 years, 43.3% did not change and 10.1% grew to >5 mm; three were removed and found to be malignant (all T1N0); the remaining 21 were followed yearly In the following year, 79 new small nodules were detected (incidence 7.9%). 11.4% were not detected in the subsequent 3 years, 79.7% did not change, 2.5% grew to > 5 mm and were followed yearly In conclusion, prevalent and incident nodules < or =5 mm detected by low-dose CT screening for lung cancer can be safely checked at 1 year intervals.

Entities:  

Mesh:

Year:  2007        PMID: 17928499     DOI: 10.1259/bjr/46019726

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  7 in total

Review 1.  Screening for lung cancer with low-dose computed tomography: a review of current status.

Authors:  Henry M Marshall; Rayleen V Bowman; Ian A Yang; Kwun M Fong; Christine D Berg
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

2.  Short- and long-term lung cancer risk associated with noncalcified nodules observed on low-dose CT.

Authors:  Paul F Pinsky; P Hrudaya Nath; David S Gierada; Sushil Sonavane; Eva Szabo
Journal:  Cancer Prev Res (Phila)       Date:  2014-04-22

3.  Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules.

Authors:  Giulia Veronesi; Eva Szabo; Andrea Decensi; Aliana Guerrieri-Gonzaga; Massimo Bellomi; Davide Radice; Stefania Ferretti; Giuseppe Pelosi; Matteo Lazzeroni; Davide Serrano; Scott M Lippman; Lorenzo Spaggiari; Angela Nardi-Pantoli; Sergio Harari; Clara Varricchio; Bernardo Bonanni
Journal:  Cancer Prev Res (Phila)       Date:  2010-12-16

4.  Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology.

Authors:  Matteo Lazzeroni; Aliana Guerrieri-Gonzaga; Davide Serrano; Maria Clara Varricchio; Giulia Veronesi; Davide Radice; Irene Feroce; Angela Nardi-Pantoli; Scott M Lippman; Eva Szabo; Bernardo Bonanni
Journal:  Contemp Clin Trials       Date:  2010-08-16       Impact factor: 2.226

Review 5.  Lung cancer screening update.

Authors:  Massimo Bellomi; Cristiano Rampinelli; Elvio De Fiori; Lorenzo Preda; Giulia Veronesi
Journal:  Cancer Imaging       Date:  2009-10-02       Impact factor: 3.909

Review 6.  Low-dose CT: technique, reading methods and image interpretation.

Authors:  Cristiano Rampinelli; Daniela Origgi; Massimo Bellomi
Journal:  Cancer Imaging       Date:  2013-02-08       Impact factor: 3.909

Review 7.  Spectrum of early lung cancer presentation in low-dose screening CT: a pictorial review.

Authors:  Cristiano Rampinelli; Sonia Francesca Calloni; Marta Minotti; Massimo Bellomi
Journal:  Insights Imaging       Date:  2016-05-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.